Introduced to the public in the form of the COVID vaccines, mRNA technology is based on decades of research. Still in the early phases, the next-generation of these therapeutics will expand beyond vaccine applications into additional disease states and showcase the technology’s prowess. But challenges remain. No common manufacturing platform currently exists and a regulatory framework is still being defined. In a recent GEN webinar, a panel of industry experts explored the evolution of mRNA technology and the innovations that are driving the conversation around manufacturing setups and regulatory decisions.
Navigating the Regulatory and Manufacturing Realities of mRNA Therapeutic Development
The regulatory and manufacturing challenges of the increasingly dynamic and multifaceted landscape of mRNA therapeutics prompts forward-looking discussions
